| Download a sample from "The Infoshop", another service of Global Information.
|
SUMMARY
Schering-Plough, based in New Jersey in the US, is a global research-based
healthcare company with leading prescription, consumer and animal health
products. This report provides a full review of the company's activities
together with sales forecasts for key products to 2010.
Schering-Plough is a global research-based healthcare company with leading
prescription, consumer and animal health products. Schering-Plough is based in
New Jersey in the US, and currently has business operations in more than 120
countries outside of the US.
Current Growth Drivers
- Remicade (infliximab) is a chimaeric monoclonal antibody that binds to
tumour necrosis factor-alpha and is indicated for a range of
inflammation-related conditions.
- Nasonex (mometasone furoate) is a mid-potency corticosteroid developed as
an aqueous nasal spray. It is marketed for the prophylaxis and treatment of
symptoms of allergies, and as Asmanex for the treatment of asthma.
- Temodar (temozolomide), an imidazotetrazine, is a cytotoxic alkylating
agent principally indicated for the treatment of glioblastoma multiforma.
- Schering-Plough has developed longer-acting forms of Intron A (a
recombinant version of a naturally-occurring interferon (IFN) alpha) which cut
dosing from three-times to once weekly. This new product is marketed as
PEG-Intron (polyethylene glycol IFN alpha-2b) for the treatment of hepatitis C.
- Vytorin (ezetimibe+simvastatin) is a fixed-combination tablet that offers
a novel approach to cholesterol management. Merck & Co and Schering Plough
developed and market this product through their cholesterol-management joint
venture franchise.
- Zetia (ezetimibe) is a cholesterol absorption inhibitor developed and
marketed through the Schering-Plough/Merck & Co joint venture.
TABLE OF CONTENTS
- Principal Operating Results
- Latest Results
EXECUTIVE SUMMARY
- Introduction
- Current Growth Drivers
- Key Late-Phase Products Reaching the Market Place
- Key Late-Stage Products
- Key Early-Stage Products
- Financial Performance 2005
- Sales and Market Position
- Income
- Expenditure
- Capital Expenditure
- R&D Expenditure
- Divisional Performance
- Sales By Business Area
- Operating Income By Business Area
- Geographic Performance
- Sales By Destination
- Long-Lived Assets By Major Country
- Sales By Origin
- Company Strategy
- Mergers, Acquisitions and Divestitures
- Key Agreements
- Production
- Employees
- Product / R&D Overview
- Key Products
- Recent Product Launches
- Recent Product Approvals
- R&D Strategy
- R&D Pipeline Overview
- Sales Forecasts
- Conclusions
PRODUCT PORTFOLIO / RESEARCH & DEVELOPMENT
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Allergy & Respiratory - Products
- Major Launched Products
- Clarinex
- Sales
- Key Markets/Indications
- Further Development
- Competitor Products
- Patents
- Generic Competition
- Sales Forecast
- Nasonex/Asmanex
- Sales
- Key Markets/Indications
- Asmanex
- Further Development
- Competitor Products
- Patents
- Sales Forecast
- Others
- Allergy & Respiratory - R&D
- CXCR2 antagonist
- Clinical Trial Results - COPD
- Allergy & Respiratory - Summary
- Growth Potential
- Limiting Factors
- Anti-Infectives - Products
- Major Launched Products
- Avelox/Avalox
- Sales
- Key Markets/Indications/Formulations
- Competitor Products
- Sales Forecast
- Noxafil
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Others
- Anti-Infectives - R&D
- Anti-Infectives - Summary
- Growth Potential
- Limiting Factors
- Antiviral - Products
- Major Launched Products
- PEG-Intron
- Sales
- Key Markets/Indications/Formulations
- Delivery Systems
- Further Development
- Competitor Products
- Lawsuits
- Sale Forecast
- Others
- Antiviral - R&D
- SCH 503034
- Clinical Trial Results - HCV
- Vicriviroc
- Antiviral - Summary
- Growth Potential
- Limiting Factors
- Anti-inflammatory - Products
- Remicade
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Patents
- Safety Issues
- Sales Forecast
- Clinical Trial Results - Juvenile Idiopathic Arthritis (JIA)
- Clinical Trial Results - Paediatric Crohn's Disease
- Anti-inflammatory - R&D
- Golimumab
- Clinical Trial Results - Rheumatoid Arthritis
- Anti-inflammatory - Summary
- Growth Potential
- Limiting Factors
- Oncology - Products
- Temodal/Temodar
- Sales
- Key Markets/Indications
- Further Development
- Sales Forecast
- Clinical Trial Results - Neuroendocrine Tumours
- Others
- Oncology - R&D
- Oncology - Summary
- Growth Potential
- Limiting Factors
- Cardiovascular - Products
- Major Launched Products
- Integrilin
- Sales
- Key Markets/Indications
- Further Development
- Sales Forecast
- Clinical Trial Results
- Vytorin
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Clinical Trial Results - Comparative Studies
- Zetia
- Sales
- Key Markets/Indications/Formulations
- Further Development
- Competitor Products
- Sales Forecast
- Clinical Trial Results - Cholesterol Regression
- Others
- Cardiovascular - R&D
- Cardiovascular - Summary
- Growth Potential
- Limiting Factors
- Others - Products
- Others - R&D
- Adenosine-2a receptor antagonist
- PDE5 inhibitor
- Suboxone
APPENDIX 1 - FINANCIAL PERFORMANCE
APPENDIX 2 - KEY AGREEMENTS
- Andrx Corporation
- Bayer
- Biogen Idec Inc
- 8th August 1996
- 18th June 1998
- 1st August 2001
- 18th October 2002
- Bristol-Myers Squibb
- Drug Royalty Corporation Inc
- Enzon Inc
- 9th October 1996
- 28th June 1999
- 23rd December 1999
- Impax Laboratories Inc
- 24th June 2002
- 27th October 2003
- Johnson & Johnson
- 25th September 1996
- 6th April 1998
- 16th August 2005
- Merck & Co
- Millennium Pharmaceuticals Inc
- 11th April 1995
- 23rd June 2004
- 1st September 2005
- Novartis
- 30th October 2002
- 1st November 2002
- 26th March 2003
- 10th April 2003
- 14th August 2006
- OncoMethylome Sciences
- Pharmacopeia Inc
- December 1994
- January 1996
- 7th October 1996
- March 1997
- 29th September 1997
- 3rd November 1998
- 18th November 1998
- 9th May 2002
- 4th September 2003
- 12th January 2004
- 5th October 2004
- 13th April 2005
- 13th March 2006
- 11th April 2006
- 17th April 2006
- 11th September 2006
- 28th September 2006
- PTC Therapeutics Inc
- Roche
- 8th January 2001
- 13th August 2001
- Sepracor Inc
- Shionogi
- 19th January 2001
- 16th November 2004
- Toyama Chemical Co Ltd
- Valeant Pharmaceuticals International
- 16th July 1998
- 7th April 1999
- 15th November 2000
- 1st August 2003
- ViroPharma Inc
- 23rd August 2004
- 3rd December 2004
- 12th January 2005
- Wyeth
- July 1991
- 18th March 1997
APPENDIX 3 - INFRASTRUCTURE
- Research and Development Facilities
- Manufacturing Facilities
APPENDIX 4 - KEY PHARMACEUTICAL SUBSIDIARIES / JOINT VENTURES
- Subsidiaries
- Joint Ventures
APPENDIX 5 - PRODUCT INDEX
Index of Tables
- Principal Operating Results
- Sales By Business Area
- Operating Income By Business Area
- Sales By Destination
- Long-Lived Assets By Major Country
- Sales By Origin
- Recent Product Launches
- Recent Product Approvals
- Key R&D Projects
- Major Products, Therapeutic Areas and Sales
- R&D Pipeline
- Major Launched Products
- Major Launched Products
- Major Launched Products
- Major Launched Products
Index of Charts
- Sales, Costs and Operating Income, 2005
- R&D Expenditure & Capital Expenditure
- Sales By Business Area, 2005
- Sales By Origin
- Employees and Productivity
- Sales of Current Major Products (2000A-2010E)
- Top Selling Products, 2005
- Clarinex Sales (2000A-2010E)
- Nasonex Sales (2000A-2010E)
- Avelox Sales (2000A-2010E)
- PEG-Intron Sales (2000A-2010E)
- Remicade Sales (2000A-2010E)
- Temodar Sales (2000A-2010E)
- Integrilin Sales (2000A-2010E)
- Vytorin Sales (2000A-2010E)
- Zetia Sales (2000A-2010E)
- Sales, Costs and Operating Income
- Profitability and Research Ratios
- R&D Expenditure and Capital Expenditure
- Current Assets, Liabilities and Ratio
- Assets, Cash and Liquidity
- Employees and Productivity
|
